GCM
TGTX icon

Graham Capital Management’s TG Therapeutics TGTX Stock Holding History

Graham Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,279
Closed -$673K – 1363
2024
Q1 		$673K Buy
+44,279
New +$705K 0.01% 540
2023
Q4 		– Sell
-19,065
Closed -$159K – 1328
2023
Q3 		$159K Buy
+19,065
New +$266K ﹤0.01% 891
2022
Q4 		– Sell
-200,313
Closed -$1.19M – 1341
2022
Q3 		$1.19M Buy
200,313
+70,821
+55% +$465K 0.05% 410
2022
Q2 		$550K Buy
+129,492
New +$809K 0.02% 640

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Graham Capital Management's TGTX Position: Q2 2024 in Review

Graham Capital Management sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 44,279 shares — an estimated $673K sold.

Graham Capital Management first reported a position in TGTX in Q2 2022 and held it in 4 quarters. The position peaked at $1.19M in Q3 2022. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Graham Capital Management reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Graham Capital Management sold 44,279 TG Therapeutics shares in Q2 2024, an estimated $673K.
  • Graham Capital Management first reported a position in TG Therapeutics in Q2 2022 and held it in 4 quarters.
  • Graham Capital Management's TG Therapeutics position peaked at $1.19M in Q3 2022.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.